The incidence rate and histological characteristics of intimal hyperplasia in elastase-induced experimental abdominal aortic aneurysms in mice

Abstract

Intimal hyperplasia (IH) is a negative vascular remodeling after arterial injury. IH occasionally occurs in elastase-induced abdominal aortic aneurysm (AAA) mouse models. This study aims to clarify the incidence and histological characteristics of IH in aneurysmal mice. A retrospective study was conducted by including 42 male elastase-induced mouse AAA models. The IH incidence, aortic diameters with or without IH, and hyperplasia lesional features of mice were analyzed. Among 42 elastase-induced AAA mouse models, 10 mice developed mild IH (24%) and severe IH was found in only 2 mice (5%). The outer diameters of the AAA segments in mice with and without IH did not show significant difference. Both mild and severe IH lesions show strong smooth muscle cell positive staining, but endothelial cells were occasionally observed in severe IH lesions. There was obvious macrophage infiltration in the IH lesions of the AAA mouse models, especially in mice with severe IH. However, only a lower numbers of T cells and B cells were found in the IH lesion. Local cell-secreted matrix metalloproteinases (MMP) 2 was highly expressed in all IH lesions, but MMP9 was only overexpressed in severe lesions. In conclusion, this study is the first to demonstrate the occurrence of aneurysmal IH and its histological characteristics in an elastase-induced mouse AAA model. This will help researchers better understand this model, and optimize it for use in AAA-related research.

Keywords

abdominal aortic aneurysms / animal model / histology / intimal hyperplasia

References

[1] Giustino G, Colombo A, Camaj A, et al. Coronary in-stent restenosis: JACC state-of-the-art review. J Am Coll Cardiol. 2022;80:348-372.

[2] Kinstner CM, Lammer J, Willfort-Ehringer A, et al. Paclitaxel-eluting balloon versus standard balloon angioplasty in in-stent restenosis of the superficial femoral and proximal popliteal artery:1-year results of the PACUBA trial. JACC Cardiovasc Interv. 2016;9:1386-1392.

[3] Allen BT, Hovsepian DM, Reilly JM, et al. Endovascular stent grafts for aneurysmal and occlusive vascular disease. Am J Surg. 1998;176:574-580.

[4] Ma S, Duan S, Liu Y, Wang H. Intimal hyperplasia of arteriovenous fistula. Ann Vasc Surg. 2022;85:444-453.

[5] Subbotin VM. Analysis of arterial intimal hyperplasia: review and hypothesis. Theor Biol med Model. 2007;4:41.

[6] Subbotin VM. Excessive intimal hyperplasia in human coronary arteries before intimal lipid depositions is the initiation of coronary atherosclerosis and constitutes a therapeutic target. Drug Discov Today. 2016;21:1578-1595.

[7] Kijani S, Vazquez AM, Levin M, Boren J, Fogelstrand P. Intimal hyperplasia induced by vascular intervention causes lipoprotein retention and accelerated atherosclerosis. Physiol Rep. 2017;5:5.

[8] Peshkova IO, Schaefer G, Koltsova EK. Atherosclerosis and aortic aneurysm-is inflammation a common denominator? FEBS J. 2016;283:1636-1652.

[9] Skotsimara G, Antonopoulos A, Oikonomou E, Papastamos C, Siasos G, Tousoulis D. Aortic Wall inflammation in the pathogenesis, diagnosis and treatment of aortic aneurysms. Inflammation. 2022;45:965-976.

[10] Xie T, Xu Y, Ji L, et al. Heme oxygenase 1/peroxisome proliferator-activated receptor gamma pathway protects intimal hyperplasia and mitigates arteriovenous fistula dysfunction by regulating oxidative stress and inflammatory response. Cardiovasc Ther. 2022;2022:7576388.

[11] Senemaud J, Caligiuri G, Etienne H, Delbosc S, Michel JB, Coscas R. Translational relevance and recent advances of animal models of abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol. 2017;37:401-410.

[12] Liu Y, Tian K, Xia C, et al. Effects of different body weights on the progression of abdominal aortic aneurysm in chow diet feeding mice:a retrospective study. Acta Laboratorium Animalis Scientia Sinica. 2022;30:57-63.

[13] Fu W, Tian K, Xia C, et al. Comparison of histological characteristics of two experimental mouse abdominal aortic aneurysm models. J Xi’an Jiaotong Univ Med Sci. 2022;43:383-389.

[14] Phie J, Thanigaimani S, Huynh P, et al. Colchicine Does Not Reduce Abdominal Aortic Aneurysm Growth in a Mouse Model. Cardiovasc Ther. 2022;5299370.

[15] Sho E, Sho M, Nanjo H, Kawamura K, Masuda H, Dalman RL. Hemodynamic regulation of CD34+ cell localization and differentiation in experimental aneurysms. Arterioscler Thromb Vasc Biol. 2004;24:1916-1921.

[16] Wang W, Xu B, Xuan H, et al. Hypoxia-inducible factor 1 in clinical and experimental aortic aneurysm disease. J Vasc Surg. 2018;68:1538-1550.e2.

[17] Xu B, Iida Y, Glover KJ, et al. Inhibition of VEGF (vascular endothelial growth factor)-a or its receptor activity suppresses experimental aneurysm progression in the aortic elastase infusion model. Arterioscler Thromb Vasc Biol. 2019;39:1652-1666.

[18] Azuma J, Asagami T, Dalman R, Tsao PS. Creation of murine experimental abdominal aortic aneurysms with elastase. J Vis Exp. 2009;29:1280.

[19] Liu H, Tian K, Xia C, et al. Kunming mouse strain is less susceptible to elastase-induced abdominal aortic aneurysms. Animal Model Exp med. 2022;5:72-80.

[20] Li Y, Zheng X, Guo J, et al. Treatment with small molecule inhibitors of advanced glycation end-products formation and advanced glycation end-products-mediated collagen cross-linking promotes experimental aortic aneurysm progression in diabetic mice. J Am Heart Assoc. 2023;12:e028081.

[21] Tian K, Xia C, Liu H, et al. Temporal and quantitative analysis of aortic immunopathologies in elastase-induced mouse abdominal aortic aneurysms. J Immunol Res. 2021:6297332.

[22] Fu Y, Liu H, Li K, et al. C-reactive protein deficiency ameliorates experimental abdominal aortic aneurysms. Front Immunol. 2023;14:1233807.

[23] Liu H, Wei P, Fu W, et al. Dapagliflozin ameliorates the formation and progression of experimental abdominal aortic aneurysms by reducing aortic inflammation in mice. Oxid Med Cell Longev. 2022:8502059.

[24] Xuan H, Xu B, Wang W, et al. Inhibition or deletion of angiotensin II type 1 receptor suppresses elastase-induced experimental abdominal aortic aneurysms. J Vasc Surg. 2018;67:573.e2-584.e2.

[25] Zhang Y, Fu Y, Zhang C, et al. MED1 deficiency in macrophages accelerates intimal hyperplasia via ROS generation and inflammation. Oxid med Cell Longev. 2021;2021:3010577.

[26] Vaglio A, Greco P, Corradi D, et al. Autoimmune aspects of chronic periaortitis. Autoimmun Rev. 2006;5:458-464.

[27] Hurks R, Vink A, Hoefer IE, et al. Atherosclerotic risk factors and atherosclerotic postoperative events are associated with low inflammation in abdominal aortic aneurysms. Atherosclerosis. 2014;235:632-641.

[28] Nordon IM, Hinchliffe RJ, Loftus IM, Thompson MM. Pathophysiology and epidemiology of abdominal aortic aneurysms. Nat Rev Cardiol. 2011;8:92-102.

[29] Fonseca DA, Antunes PE, Antunes MJ, Cotrim MD. Histomorphometric analysis of the human internal thoracic artery and relationship with cardiovascular risk factors. PloS One. 2019;14:e0211421.

[30] Cizek SM, Bedri S, Talusan P, Silva N, Lee H, Stone JR. Risk factors for atherosclerosis and the development of preatherosclerotic intimal hyperplasia. Cardiovasc Pathol. 2007;16:344-350.

[31] Cooper JB, Greisman JD, Dakay K, et al. Incidence of neo-intimal hyperplasia in anterior circulation aneurysms following pipeline flow diversion. J Stroke Cerebrovasc Dis. 2021;30:105794.

[32] Li Y, Zhang J. Animal models of stroke. Animal Model Exp Med. 2021;4(3):204-219.

[33] Zhang LN, Parkinson JF, Haskell C, Wang YX. Mechanisms of intimal hyperplasia learned from a murine carotid artery ligation model. Curr Vasc Pharmacol. 2008;6:37-43.

[34] Low EL, Baker AH, Bradshaw AC. TGFbeta, smooth muscle cells and coronary artery disease: a review. Cell Signal. 2019;53:90-101.

[35] Feng L, Ma X, Wang J, Tian Q. Up-regulation of 14-3-3beta plays a role in intimal hyperplasia following carotid artery injury in diabetic Sprague Dawley rats by promoting endothelial cell migration and proliferation. Biochem Biophys Res Commun. 2017;490:1237-1243.

[36] Guo J, Shoji T, Ge Y, et al. Treatment with the prolyl hydroxylase inhibitor JNJ promotes abdominal aortic aneurysm progression in diabetic mice. Eur J Vasc Endovasc Surg. 2022;63:484-494.

[37] Shoji T, Guo J, Ge Y, et al. Type I interferon receptor subunit 1 deletion attenuates experimental abdominal aortic aneurysm formation. Biomolecules. 2022;12:1541.

RIGHTS & PERMISSIONS

2023 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.